## 2 Introduction  
The history of innovative laser applications demonstrates its ubiquitous character. The feasibility of using lasers for hadron radiotherapy has been considered for more than a decade based on energetic ion yields from intense laser-plasma experiments. It has been one of the main applications considered in laser-driven ion acceleration studies [13; 14; 15; 16; 17; 18; 19; 20; 21; 22]. We also include in this work laser driven electron beams for radiation therapy and radiobiology [23; 24] as well as laser driven proton beams for radiobiological studies [25; 26; 27]. Moreover for completeness we have included finally a section dealing with laser driven fragmentation studies as a very recent cancerous tissue diagnostic which has received much attention in the last year (see Section 7).  
Laser technology and relevant laser-plasma physics as drivers are advancing rapidly. Outstanding progress has been made in high-power laser technology in the last decade with laser powers reaching the petawatt (PW) level. At present, there are fifteen PW lasers built or being built around the world while even higher power lasers (exawatt and beyond) are being considered by some. With adequate focusing petawatt lasers can generate peak electric fields of order \(10^{12}\) V/cm with relatively efficient conversion to relativistic electrons with energies in excess of 1 GeV. In turn these electrons can generate beams of protons, heavy ions, neutrons and high-energy photons. Given the potential for energetic laser-driven particles we can now consider experiments in laser laboratories that are normally associated with conventional nuclear accelerators and reactors. A number of reviews describing the production of ion and electron beams by intense laser irradiation have been published during the last few years, e.g., [13; 14; 15; 16].  
In 2007 [28] [PERSON] and [PERSON] published a seminal paper entitled \"What will it take for laser driven proton accelerators to be applied to tumor therapy\" which acknowledged the potential of a compact laser based system but warned that the optimism of laser physicists should not raise undue expectations in the medical community. Reduced cost and size are shared general aims in laser-driven particle beam development for radiotherapy. However, many scientific and technical challenges must first be met to achieve this and to confirm unique laser-driver capabilities. Reaching medically relevant particle kinetic energies is obviously essential, yet equally important is the demonstration of repetition-rated, well-controlled beamlines at these energies with suitable bunch parameters that are highly reproducible. A systems mindset is necessary to incorporate, optimize and even exploit the multiple technologies that must be combined. We can refer to the full system as the integrated laser-driven ion accelerator system or ILDIAS (ILDEAS for electrons). ILDIAS components therefore include the laser driver, the laser target, instrumentation for diagnostics and control and beam line (ion) optics. In this novel accelerator we can regard the laser plus target (which includes the induced laser-plasma at the target) as the accelerator source.  
The limited scope of this work is to review global progress toward laser-driven hadron therapy specifically in terms of particle kinetic energy and other intrinsic source features (such as angular divergence and duration of the emitted particle bunch) of the laser-driven acceleration in a plasma environment.